Columbia Ophthalmologist Dr. Brian Marr speaks about an experimental immunotherapy
designed to attack melanoma that has improved one-year survival, according to CUIMC reports.
The drug trial, led by Columbia Cancer Researcher Richard Carvajal, MD, was conducted
with a small group of patients with advanced uveal melanoma, the most common primary eye
cancer in adults. Read the full story, here.
Caption: Dr. Marr treating a patient at ColumbiaDoctors Third Ave.